Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terbinafine vs Griseofulvin in Children With Tinea Capitis
NCT00117767Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2004
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Terbinafine in tinea capitis (2 arms), sponsored by Novartis. Primary endpoint: Complete cure (negative mycology and clinical cure) rate at 10 weeks. Started Jun 2004; status: completed.
02
Drugs
Terbinafine
03
Conditions
tinea capitis
Beyond the preview
Go deeper on NCT00117767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117767.